HUMIRA can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. HUMIRA has been shown to reduce the rate of progression of ...
HUMIRA can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. HUMIRA has been shown to reduce the rate of progression of ...
Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of year two data from AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis (RA) Subjects With ...
man hands gout arthritis The trial compares short- and long-term outcomes of Cimzia and Humira in RA WASHINGTON, DC—Data from a head-to-head superiority trial comparing Cimzia (certolizumab pegol) and ...
Xeljanz and Xeljanz XR are Janus kinase (JAK) inhibitors indicated to treat moderately to severely active rheumatoid arthritis when methotrexate therapy is inadequate. The non-inferiority study found ...
SAN DIEGO — Erinn Maury knew Remicade wasn't the right drug for Patti Schulte, a rheumatoid arthritis patient the physician saw at her Millersville, Maryland, practice. Schulte's swollen, painful ...
Please provide your email address to receive an email when new articles are posted on . Methotrexate increases the probability of remission with adalimumab or infliximab by 50% in patients with ...
Findings from a landmark clinical trial in pediatric Crohn's disease show a clear benefit of adding methotrexate to treatment with the tumor necrosis factor inhibitor (TNFi) adalimumab (Humira), but ...
MONTREAL, Feb. 20, 2019 /CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that Health Canada has approved HUMIRA® (adalimumab) for the treatment of ...
Please provide your email address to receive an email when new articles are posted on . Olokizumab demonstrated superiority compared with placebo and non-inferiority compared with adalimumab in ...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has voted to recommend marketing authorization for Imraldi (adalimumab, Samsung Bioepsis UK Limited) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results